NDA filing for ET-202 Accepted for Review and Assigned PDUFA Date of October 21, 2019 DEER PARK, Ill. , March 25, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, reported
FDA Previously Granted DS-200 Fast Track Designation DEER PARK, Ill. , March 14, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), today announced that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration ( FDA ) for DS-200 via the
DEER PARK, Ill. , Feb. 21, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that Sean Brynjelsen , Chief Executive Officer, will participate in a fireside chat
If Approved, EM-100 Will Be the First OTC Preservative-Free Formulation of Its Kind EM-100 Has Been Submitted to the FDA for Review LAVAL, Quebec and DEER PARK, Ill., Feb. 19, 2019 – Bausch Health Companies Inc. (NYSE/TSX: BHC) and Bausch + Lomb, its wholly owned subsidiary and a leading global eye
Transaction adds an additional potential 2019 product launch to Eton’s pipeline ET-202 NDA was submitted in December 2018 ; PDUFA date expected to be in Q4 2019 ET-203 NDA expected to be submitted by Q3 2019 DEER PARK, Ill. , Feb. 11, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc.
New Drug Application expected to be filed in 2019 DEER PARK, Ill. , Jan. 24, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it has entered into a
